20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
KeyBanc Capital Markets has initiated coverage on Alpha Teknova Inc (NASDAQ:TKNO) with a Sector Weight rating.
Alpha Teknova is a pure play on the reagents and consumables needed in a lab for cell therapy production, synthetic biology, and other processes.
Teknova's emphasis on ready-to-use products, short lead times, and scale attracts customers.
KeyBanc notes that if Cell & Gene Therapies achieve their potential success, Alpha Teknova will be a significant research technology provider for many programs.
The analyst notes five Cell & Gene Therapies approvals in 2022, with an expected 10-14 approvals or accepted filings by the EU and the FDA in 2023.
Successful Cell & Gene Therapies approvals and successful TKNO revenue results will increase confidence that TKNO can accelerate revenue growth.
The analyst writes that the company's customers include early-stage biotech, and revenue should only show low-single-digit growth in 2023 due to funding constraints.
The company is raising capital through an at-the-market program, and the analyst estimates that about $10-$20 million of capital is needed.
The analyst also notes that the completion of the company's Hollister, CA, facility and $200 million in revenue is possible, but the utilization rate is uncertain.
Price Action: TKNO shares are up 5.92% at $3.04 on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!